

## Prof. Başak OYAN ULUÇ

### Personal Information

Office Phone: [+90 216 649 5172](tel:+902166495172)

Email: [basak.uluc@acibadem.edu.tr](mailto:basak.uluc@acibadem.edu.tr)

Web: <https://avesis.acibadem.edu.tr/basak.uluc>

### Foreign Languages

English, C1 Advanced

### Certificates, Courses and Trainings

Health&Medicine, Eğitici Gelişimi Temel Kursu (online), Acibadem Mehmet Ali Aydınlar Üniversitesi, 2020

### Dissertations

Post Doctorate of Medicine, Diffüz büyük B hücreli lenfomalarda sağkalım ve prognostik faktörler, Hacettepe University, Sağlık Bilimleri Enstitüsü, Klinik Onkoloji A.B.D., 2004

Expertise In Medicine, Opere Evre I-III Meme Kanserlerinde Adjuvan Siklofosfamid-Adriamisin-5-Flourourasil (CAF) Kemoterapisi Sonuçları ve Prognozu Etkileyen Faktörler, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2001

### Research Areas

Medicine, Oncology

### Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydınlar University, School of Medicine, Department of Medical Sciences, 2017 - Continues

Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2012 - 2016

Associate Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2006 - 2012

Assistant Professor, Yeditepe University, Faculty Of Medicine, Department Of Internal Medicine, 2006 - 2006

### Academic and Administrative Experience

Head of Department, Yeditepe University, Faculty Of Medicine, Department Of Basic Medical Sciences, 2008 - 2016

### Courses

Kanser epidemiyolojisi ve etyolojisi, Undergraduate, 2020 - 2021

Epidemiology and etiology of cancer, Undergraduate, 2018 - 2019, 2019 - 2020

Hangi kanserler için toplum taraması ne zaman ve nasıl yapılmalıdır?, Undergraduate, 2020 - 2021

Medikal Onkoloji, Postgraduate, 2020 - 2021

Epidemiology and etiology of cancer, Undergraduate, 2017 - 2018

## Advising Theses

Oyan Uluç B., Sönmez Ö., Yüksek gradlı gliyal tümörlerde tanıda ve nükste PD-L1 ekspresyonu değişimi, Expertise In Medicine, H.ŞEYMA(Student), 2016

Oyan Uluç B., Progrese gliyal tümörlerde mgmt (metil guanin-dna metil transferaz) metilasyonu ve idh (izositrat dehidrojenaz) mutasyonunda değişimin incelenmesi ve prognoza etkisinin araştırılması, Expertise In Medicine, M.AKİF(Student), 2014

Oyan Uluç B., Acute effects of Palonosetron on ECG parameters in cancer patients. , Post Doctorate of Medicine, C.AKOSMAN(Student), 2010

Oyan Uluç B., The prognostic relevance of response evaluation to chemotherapy using FDG-PET/CT in patients with advanced stage non-small-cell lung cancer, Post Doctorate of Medicine, Ç.ORDU(Student), 2010

## Jury Memberships

Associate Professor Exam, Associate Professor Exam, Acıbadem Mehmet Ali Aydınlar Üniversitesi, October, 2020

Associate Professor Exam, Associate Professor Exam, NECMETTİN ERBAKAN ÜNİVERSİTESİ/MERAM TIP FAKÜLTESİ, October, 2020

Appointment Academic Staff, Appointment Academic Staff, Acıbadem Mehmet Ali Aydınlar Üniversitesi, August, 2020

Associate Professor Exam, Associate Professor Exam, NECMETTİN ERBAKAN ÜNİVERSİTESİ, March, 2020

Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, October, 2019

Appointment Academic Staff, Appointment Academic Staff, Acıbadem Mehmet Ali Aydınlar Üniversitesi, October, 2019

Associate Professor Exam, Associate Professor Exam, Yeditepe Üniversitesi, May, 2015

Appointment Academic Staff, Appointment Academic Staff, Koç Üniversitesi, February, 2015

Appointment Academic Staff, Appointment Academic Staff, Mersin Üniversitesi, January, 2015

Associate Professor Exam, Associate Professor Exam, Hacettepe Üniversitesi, November, 2014

Appointment Academic Staff, Appointment Academic Staff, Selçuk Üniversitesi, May, 2014

Appointment Academic Staff, Appointment Academic Staff, Acıbadem Mehmet Ali Aydınlar Üniversitesi, October, 2013

Appointment Academic Staff, Appointment Academic Staff, Yeditepe Üniversitesi, June, 2013

Expertise In Medicine, Expertise In Medicine, Yeditepe Üniversitesi, October, 2012

## Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

### I. Identifying Knowledge and Practices regarding Cancer Patient Malnutrition: A Survey Study among Oncologists

SÖNMEZ Ö., Tezcanli E., Bas D., Kazanci H. B. , Altinok A., Demir A., OYAN ULUÇ B.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2021 (Journal Indexed in SCI)

### II. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Ak N., Ozkan B., Yenigun M. B. , Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al.

JOURNAL OF BUON, vol.26, no.3, pp.819-829, 2021 (Journal Indexed in SCI)

### III. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., Demirkazık A., Sak S. D. , Dilege S., Tanju S., Toker A., et

al.

JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)

- IV. **A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)**  
Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacıoglu B., Oktay E., Erdem D., Arpacı E., Oyan Uluc B., Turhal S., et al.  
JOURNAL OF BUON, vol.24, no.1, pp.242-248, 2019 (Journal Indexed in SCI)
- V. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**  
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M., Aksoy S., Aktas B., Ozdemir O., Alacacioglu A., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (Journal Indexed in SCI)
- VI. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**  
KILIÇKAP S., Ozturk A., Karadurmus N., Korkmaz T., YUMUK P. F. , Cicin I., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- VII. **Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.**  
Oyan B., Sonmez Ö., Yazar A., Teomet M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- VIII. **Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study.**  
Eren O., Ozturk M., Sonmez Ö., Oyan B.  
American journal of therapeutics, vol.23, 2016 (Journal Indexed in SCI Expanded)
- IX. **Is It Time for Maintenance Chemotherapy for Advanced Gastric Adenocarcinoma?**  
Eren O., Sönmez Ö., Oyan B.  
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, pp.2067, 2016 (Journal Indexed in SCI Expanded)
- X. **Bilateral synchronous adrenal metastasis of invasive ductal carcinoma treated with multimodality therapy including adrenalectomy and oophorectomy.**  
Eren O., Ordu C., Selcuk N., Akosman C., Ozturk M., Özkan F., Gokce Ö., Oyan B.  
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.22, pp.157-60, 2016 (Journal Indexed in SCI Expanded)
- XI. **May there be a role for hormonal manipulation for treatment of hormone receptor negative breast cancer?**  
Onder E., Uysal S., Oyan B.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.1380, 2015 (Journal Indexed in SCI Expanded)
- XII. **Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study.**  
Abali H., ÇELİK İ., Karaca B., Turna H., Sağlam E. K. , Akman T., Oztop I., COŞKUN H. Ş. , Turhal N. S. , Sezer A., et al.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.4, pp.1137-41, 2015 (Journal Indexed in SCI)
- XIII. **Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature.**  
Akosman C., Ordu C., Eroglu E., Oyan B.  
American journal of therapeutics, vol.22, no.3, 2015 (Journal Indexed in SCI)
- XIV. **Revisiting post-gastrectomy anemia with a brief survey among a group of Turkish medical oncologists.**  
Eren O., Sonmez Ö., Ozkan H., Oyan B.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.808-11, 2015 (Journal Indexed in

SCI Expanded)

- XV. **Voltage-gated sodium channel blockers can augment the efficacy of chemotherapeutics by their inhibitory effect on epithelial-mesenchymal transition.**  
Eren O, Ozturk M., Sonmez Ö., Oyan B.  
Medical hypotheses, vol.84, pp.11-3, 2015 (Journal Indexed in SCI Expanded)
- XVI. **Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer.**  
Ordu C., Selcuk N., Akosman C., Eren O., Altunok E., Toklu T., Oyan B.  
Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.321-6, 2015 (Journal Indexed in SCI Expanded)
- XVII. **Gastric metastasis in a patient with lobular breast carcinoma 6 years after diagnosis.**  
Eren O., Ozturk M., Sonmez Ö., Aslan E., Ozkan F., Oyan B.  
Journal of gastrointestinal cancer, vol.45, pp.504-5, 2014 (Journal Indexed in SCI Expanded)
- XVIII. **Pituitary metastasis of colon adenocarcinoma: a rare occurrence.**  
Ozturk M., Eren O., Sarikaya B., Aslan E., Oyan B.  
Journal of gastrointestinal cancer, pp.85-7, 2014 (Journal Indexed in SCI Expanded)
- XIX. **Voltage-gated sodium channel blockade for inhibition of EMT.**  
Eren O., Oyan B.  
Trends in pharmacological sciences, vol.35, pp.621, 2014 (Journal Indexed in SCI)
- XX. **Should we be more cautious about replacement of vitamin B12 in patients with cancer receiving cytotoxic chemotherapy?**  
Eren O., Ozturk M., Sonmez Ö., Oyan B.  
Medical hypotheses, vol.83, pp.726-9, 2014 (Journal Indexed in SCI Expanded)
- XXI. **Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.**  
Rordorf T., Hassan A. A. , Azim H., Alexandru E., Er O., GÖKMEN E., Gural Z., Mardiak J., Minchev V., Peintinger F., et al.  
Breast (Edinburgh, Scotland), vol.23, no.5, pp.511-25, 2014 (Journal Indexed in SCI)
- XXII. **Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?**  
Eren O., Ozturk M., Oyan B.  
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol.22, pp.2599-600, 2014 (Journal Indexed in SCI)
- XXIII. **Does cetuximab cause small bowel perforation?**  
Ozturk M., Eren O., Oyan B.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.865, 2014 (Journal Indexed in SCI)
- XXIV. **Reply to the letter to the editor 'Are male gender and nonadenocarcinoma histology valid prognostic factors for breast cancer?' by Eren et al.**  
Eren O., Ozturk M., Sonmez Ö., Oyan B.  
ANNALS OF ONCOLOGY, vol.25, no.4, pp.911, 2014 (Journal Indexed in SCI)
- XXV. **Gallbladder perforation related to bevacizumab.**  
Ozturk M., Kalayci M., Oyan B.  
Clinics and research in hepatology and gastroenterology, vol.37, 2013 (Journal Indexed in SCI)
- XXVI. **HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.**  
Dent S., Oyan B., Honig A., Mano M., Howell S.  
Cancer treatment reviews, vol.39, pp.622-31, 2013 (Journal Indexed in SCI)
- XXVII. **Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.**  
Ozturk M., Ozveren O., Cinar V., Erdik B., Oyan B.  
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, vol.24, pp.90-4, 2013 (Journal Indexed in SCI)
- XXVIII. **Why do targeted agents not work in the adjuvant setting in colon cancer?**  
Oyan B.

- Expert review of anticancer therapy, vol.12, pp.1337-45, 2012 (Journal Indexed in SCI)
- XXIX. **Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.**  
Oyan B.  
Medical hypotheses, vol.77, pp.1028-30, 2011 (Journal Indexed in SCI)
- XXX. **The early metabolic effect of zoledronic acid on FDG-PET scans in patients with bone metastasis**  
Selcuk N. A. , Uluc B., Akosman C., Ordu C., Toklu T.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (Journal Indexed in SCI)
- XXXI. **Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment.**  
Akosman C., Selcuk N. A. , Ordu C., Ercan S., Ekici I. D. , Oyan B.  
Cancer imaging : the official publication of the International Cancer Imaging Society, vol.11, no.1, pp.52-5, 2011 (Journal Indexed in SCI)
- XXXII. **The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**  
Ordu C., Selcuk N. A. , Akosman C., Oyan B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXIII. **The acute effects of palonosetron on ECG parameters in patients with cancer**  
Akosman C., Ordu C., Oyan B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXIV. **The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small cell lung cancer**  
Ordu C., Selcuk N. A. , Akosman C., Oyan B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXXV. **High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.**  
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.  
Clinical transplantation, vol.23, pp.839-47, 2009 (Journal Indexed in SCI)
- XXXVI. **Validation of FDG-PET/CT in evaluation of early remission in patients with refractory lymphoma after treatment with high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)**  
Selcuk N. A. , Civi G., Toklu T., Oyan B.  
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.36, 2009 (Journal Indexed in SCI)
- XXXVII. **The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients.**  
Yavas O., Yazici M., Eren O., Oyan B.  
Swiss medical weekly, vol.137, pp.556-8, 2007 (Journal Indexed in SCI)
- XXXVIII. **Hemorrhagic cystitis due to viral infection following hematopoietic stem cell transplantation**  
Obek C., Kocagoz T., Aktas S., Yencilek F., Uluc B., Koc Y.  
JOURNAL OF ENDOUROLOGY, vol.21, 2007 (Journal Indexed in SCI)
- XXXIX. **Current medical treatment of pancreatic neuroendocrine tumors.**  
Yalcin S., Oyan B., Bayraktar Y.  
Hepato-gastroenterology, vol.54, pp.278-84, 2007 (Journal Indexed in SCI)
- XL. **High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.**  
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.  
Leukemia & lymphoma, vol.47, pp.1545-52, 2006 (Journal Indexed in SCI)
- XLI. **Adding a single high-dose chemotherapy cycle to three cycles of standard salvage chemotherapy for relapsed germ-cell tumours does not improve clinical outcomes.**  
Oyan B.  
Cancer treatment reviews, vol.32, pp.45-9, 2006 (Journal Indexed in SCI)
- XLII. **Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-**

**cell tumors failing first-line platinum chemotherapy?**

Oyan B., Koc Y.

Annals of oncology : official journal of the European Society for Medical Oncology, vol.17, pp.349-50, 2006  
(Journal Indexed in SCI)

- XLIII. **Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis.**  
Oyan B., Koc Y., Emri S., Kansu E.  
Medical oncology (Northwood, London, England), vol.23, pp.125-9, 2006 (Journal Indexed in SCI)
- XLIV. **Prevalence and correlates of metabolic syndrome (MS) in older adults.**  
Cankurtaran M., Halil M., Yavuz B., Dagli N., Oyan B., Ariogul S.  
Archives of gerontology and geriatrics, vol.42, pp.35-45, 2006 (Journal Indexed in SCI)
- XLV. **Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.**  
Oyan B., Koc Y., Ozdemir E., Kars A., Turker A., Tekuzman G., Kansu E.  
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol.11, pp.688-97, 2005 (Journal Indexed in SCI)
- XLVI. **Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.**  
Abali H., Oyan B., Guler N.  
Chemotherapy, vol.51, pp.280-5, 2005 (Journal Indexed in SCI)
- XLVII. **IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.**  
Abali H., Oyan B., Koc Y., Kars A., Barista I., Uner A., Turker A., Demirkazik F., Tekin F., Tekuzman G., et al.  
American journal of clinical oncology, vol.28, pp.264-9, 2005 (Journal Indexed in SCI)
- XLVIII. **Successful salvage with high-dose sequential chemotherapy coupled with in vivo purging and autologous stem cell transplantation in 2 patients with primary refractory mantle cell lymphoma presenting in the leukemic phase.**  
Oyan B., Koc Y., Kansu E.  
International journal of hematology, vol.81, pp.155-8, 2005 (Journal Indexed in SCI)
- XLIX. **A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.**  
Koc Y., Oyan B., Kars A., Tekuzman G., Canpinar H., Kansu E.  
Hematological oncology, vol.22, pp.43-53, 2004 (Journal Indexed in SCI)
- L. **Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?**  
Oyan B., Altundag K., Ozisik Y.  
American journal of clinical oncology, vol.27, pp.210-1, 2004 (Journal Indexed in SCI)
- LI. **Prognostic factors and outcome in 306 patients with diffuse large B-cell lymphoma (DLBCL)**  
Oyan B., Tekuzman G., BARIŞTA İ., Ozisik Y., kars A., Turker A., YALÇIN Ş., Guler N., Koc Y., Kansu E.  
ANNALS OF ONCOLOGY, vol.15, pp.153, 2004 (Journal Indexed in SCI)
- LII. **Epithelioid sarcoma of vulva - A case report and review of the literature**  
Altundag K., Dikbas O., Oyan B., Usubutun A., Turker A.  
MEDICAL ONCOLOGY, vol.21, no.4, pp.367-372, 2004 (Journal Indexed in SCI)
- LIII. **Idiopathic fibrosclerosis of bilateral orbits, bilateral ureters, thyroid: a case report and review of the literature.**  
Cankurtaran M., Oyan B., Kiliçkap S., Yavuz B., Batman F.  
International urology and nephrology, vol.36, pp.495-8, 2004 (Journal Indexed in SCI Expanded)
- LIV. **Thymic malignancy in a breast cancer patient--is there an association with anti-estrogenic effects of tamoxifen?**  
Oyan B., Aksoy S., Yavas O., Kars A., Turker A., Barista I.  
Acta oncologica (Stockholm, Sweden), vol.43, pp.115-6, 2004 (Journal Indexed in SCI)

- LIV. **Generalized lymphadenopathy - A rare presentation of disseminated prostate cancer**  
Oyan B., Engin H., Yalcin S.  
MEDICAL ONCOLOGY, vol.19, no.3, pp.177-179, 2002 (Journal Indexed in SCI)
- LVI. **Breast cancer and splenic non-Hodgkin's lymphoma, a rare occurrence [1]**  
Engin H., Baltali E., Oyan B., Göksel H., Demirel B.  
Breast Journal, vol.8, no.6, pp.400-401, 2002 (Journal Indexed in SCI Expanded)

## Articles Published in Other Journals

- I. **Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak**  
Sezer A., Cicin İ., Karadeniz Ç., Özkan G., Başaran G., Oyan B., Eralp Y., Güllüoğlu B., Turkish N.  
Turkish Journal of Surgery, vol.36, no.2, pp.147-163, 2020 (Journal Indexed in ESCI)
- II. **An unusual cause of arthritis: Carcinoma metastases**  
ÖZLER T., SÖNMEZ Ö., EREN O. Ö., DOĞAN EKİCİ A. I., GÜVEN M., ÇAĞATAY U., OYAN ULUÇ B.  
Yeditepe Medical Journal , 2014 (Other Refereed National Journals)
- III. **Successful allogeneic marrow transplantation from donors with hematologic malignancies**  
Koç Y., Oyan B., Akhtar M. S., Schenkein D. P., Miller K. B.  
Turkish Journal of Cancer, vol.34, no.3, pp.118-121, 2004 (Refereed Journals of Other Institutions)
- IV. **Hematopoietic stem cell transplantation in hematologic malignancies and solid tumors: Hacettepe University Institute of Oncology experience**  
Oyan B., Koç Y., Kars A., Türker A., Akyüz C., Güç D., Üner A., Ruacan Ş., Yiğitbaş E., Canpınar H., et al.  
Turkish Journal of Cancer, vol.33, no.1, pp.27-39, 2003 (Refereed Journals of Other Institutions)
- V. **The prognostic factors for local disease free survival and distant disease free survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamide-adriamycin-5-fluorouracil (CAF) chemotherapy** Adjuvan siklofosfamid-adriamisin-5-florourasil (CAF) kemoterapisi alan opere evre I-III meme kanserli hastalarda lokal nüksüz ve uzak nüksüz sağkalimi etkileyen prognostik faktörler  
Oyan B., Güler N., Tekuzman G., Kars A., Türker A., Altundağ M. K., Özişik Y., Baltali E., Çelik I., Hamaloğlu E., et al.  
THOD - Turk Hematoloji-Onkoloji Dergisi, vol.12, no.3, pp.115-125, 2002 (Refereed Journals of Other Institutions)
- VI. **The prognostic predictors for disease free survival and overall survival in stage I-III breast cancer patients treated with adjuvant cyclophosphamideadriamycin-5-fluorouracil (CAF) chemotherapy**  
Oyan B., Güler N., Kars A., Türker A., Altundağ K., Özişik Y., Baltali E., Çelik I., Barışta I., Güllü I., et al.  
Turkish Journal of Cancer, vol.32, no.3, pp.92-104, 2002 (Refereed Journals of Other Institutions)

## Books & Book Chapters

- I. **Akciğer kanserinde hedefe yönelik tedavilerde güncel durum**  
Oyan Uluç B.  
in: Akciğer Kanseri, Meftun Ünsal, Editor, Türkiye Klinikleri Yayınevi, İstanbul, pp.52-58, 2021
- II. **Erken evre ve lokal ileri evre meme kanserinde sistemik tedavi**  
Oyan Uluç B.  
in: Meme Hastalıkları, Cihan Uras, Editor, Nobel Yayın Dağıtım, İstanbul, pp.223-242, 2021

## Refereed Congress / Symposium Publications in Proceedings

- I. **Relationship of Vitamin D Receptor Gene Polymorphisms with Adverse Drug Responses In Patients With Colorectal Cancer**  
Tosun M., Çevik M., Sönmez Ö., Er Ö., Demir O. G., Oyan Uluç B., Güven Mert A., Deliorman G., Karaalp A., Süsleyici

Duman B.

9th International Molecular Biology and Biotechnology Congress, Kars, Turkey, 6 - 10 December 2020

- II. **Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey**  
Başaran G., Demirci U., Yıldız F., Çiçin İ., Aktaş B. Y., Öztürk B., Sezgin Göksu S., Coşkun H. Ş., Oyan Uluç B., Sönmez Ö., et al.  
American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 29 - 31 May 2020, pp.13055
- III. **Risks and characteristics of early-onset colorectal cancer: A single center retrospective study**  
Yazar A., Koç E. S., Tözün A. N., Kutsal N. E., Önder F. O., Aygün C., Oyan Uluç B.  
Proceedings of the World Congress of Gastroenterology, İstanbul, Turkey, 21 - 24 September 2019, pp.383
- IV. **OnkoTürk Kayıt Sistemi: Solid Organ Maligniteli Hastalarda Tedavi ve İzlem Tercihlerinin Belirlenmesine Yönelik Kayıt Çalışması Ara Değerlendirme Sonuçları**  
Alan Ö., Yumuk P. F., Dane F., Akgül Babacan N., Coşkun H. Ş., Sezgin Göksu S., Çelik İ., Oyan Uluç B., Yücel İ.  
23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.292
- V. **Distribution of ADC-Ki67 with molecular subtypes labels**  
Aksoy Özcan Ü., Ulus S., Ekemen S., Oyan Uluç B., Ozcan İ. A.  
25th European Congress of Radiology (ECR) 2019, Vienna, Austria, 27 February - 03 March 2019, pp.1
- VI. **Testing machine learning algorithms' performance for non-invasively identifying breast cancer molecular subtypes using BI-RADS evaluations**  
Özcan İ. A., Aksoy Özcan Ü., Ekemen S., Ulus S., Oyan Uluç B.  
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5
- VII. **Correlation of proliferation index markers (Ki-76 and PHH3) with breast MRI apparent diffusion coefficient values**  
Ekemen S., Özcan A., Aksoy Özcan Ü., Ulus S., Oyan Uluç B.  
San Antonio Breast Cancer Symposium, Texas, United States Of America, 4 - 10 December 2018, vol.79, no.4, pp.5
- VIII. **Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results**  
Esin E., Oksuzoglu O. B. C., Bilici A., Cicin I., Aksoy S., Alacacioglu A., Kaplan M. A., Cabuk D., Sumbul A. T., Paydas S., et al.  
43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29, pp.104-105
- IX. **Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors**  
Oyan Uluç B., Sönmez Ö., Yazar A., Teomete M.  
American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, United States Of America, 1 - 05 June 2018, pp.2436
- X. **Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival**  
Oyan B., Eren S., Sonmez O., Ozkan F., Yaltirak K., Ture U.  
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- XI. **PD-L1 expression of high grade glial tumors at diagnosis and change of expression status at recurrence.**  
Oyan B., Eren S., Sonmez Ö., Ozkan F., Yaltirak K., Ture U.  
53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2017, vol.35
- XII. **Immunotherapy related cardiomyopathy.**  
Sonmez Ö., Sever O. N., Oyan B., Demir O. G.  
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 07 June 2017, vol.35
- XIII. **Primary peritoneal hepatoid adenocarcinoma: Response to platin based chemotherapy.**



Oyan B., Sonmez Ö., Eren O. O. , Ozkan F., Ozgen A.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34

- XIV. **The change in the status of MGMT methylation and IDH mutation in initial and recurrent glial tumors and its relation with prognosis.**  
Oyan B., Ozturk M. A. , Ozkan F., Eren O. O. , Sonmez Ö.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Capecitabine maintenance after first-line induction chemotherapy with docetaxel cisplatin, and fluorouracil in patients with advanced gastric cancer**  
Oyan B., Eren O. O. , Sonmez Ö.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVI. **Gallbladder perforation related to bevacizumab in a patient with lung adenocarcinoma.**  
Oyan B., Ozturk M. A. , Kalayci M.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVII. **The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.**  
Ozturk M., Ozaydin S., Oyan B., Ozbalak M., Arpacı F., Paydas S., Ataergin S., Ferhanoglu B., Kocak N., Gurkan E., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XVIII. **Hematopoietic stem cell transplantation for hematological diseases at yeditepe university hospital**  
Yirmibescik S., Senkal V., Kalayci G., Aktas S., Aydin D., Sonmezoglu M., Kocagoz S., Oyan B.  
Tandem BMT Meeting 2007, Colorado, United States Of America, 8 - 12 February 2007, vol.13, pp.94
- XIX. **Nephrologic complications in stem cell transplantation**  
Yakupoglu Ü., Uluc B., Koc Y.  
44th ERA-EDTA Congress, Barcelona, Spain, 22 - 24 June 2007, vol.22, pp.56-57
- XX. **Tropisetron does not induce arrhythmia in chemo-naive otherwise healthy cancer patients.**  
Abali H., Abali G., Oksuzoglu B., Bakar M., Budakoglu B., Oyan B., Aytemur K., Zengin N.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXI. **High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL**  
Oyan B., Koc Y., Ozdemir E., Kansu E.  
31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35
- XXII. **High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)**  
Oyan B., Koc Y., Ozdemir E., Kansu E.  
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104
- XXIII. **Nonmyeloablative allogeneic stem cell transplantation: Hacettepe University Institute of Oncology Experience.**  
Koc Y., Ozdemir E., Oyan B., Kansu E.  
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104

- XXIV. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**  
Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.  
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXV. **Granisetron plus alprazolam versus granisetron alone in the control of emesis in patients with operable breast cancer receiving anthracycline containing chemotherapy: A phase III trial.**  
Abali H., Oyan B., Ozisik Y., Guler N.  
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXVI. **Outcome of well differentiated thyroid cancer: Single institution results.**  
Aksoy S., Abali H., Kilickap S., Yavas O., Oyan B., Elkiran E., Aras T., Ugurlu O., Guler N., Tekuzman G.  
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXVII. **Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.**  
Oyan B., Koc Y., Kars A., Turker A., Tekuzman G., Kansu E.  
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102
- XXVIII. **Primary papillary serous carcinoma of the peritoneum: A retrospective analysis of 13 cases**  
Oyan Uluç B., Abali H., Güler N., Kars A., Barışta İ., Tekuzman G.  
ASCO Annual Meeting, Illinois, United States Of America, 31 May - 03 June 2003, vol.22, pp.1962
- XXIX. **Successful salvage with high-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with Rituximab in patients with primary refractory mantle cell lymphoma presenting in leukemic phase.**  
Oyan B., Koc Y., Tekin F., Kansu E.  
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100
- XXX. **IIVP salvage regimen induces high response rates in patients with relapsed FED or NHL prior to autologous HSCT.**  
Abali H., Koc Y., Oyan B., Tekin F., Tekuzman G., Kansu E.  
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100

## Activities in Scientific Journals

Kanser Gündemi-Meme Kanseri Sayısı, First Editor, 2020 - 2020

Journal Of Oncological Sciences, Assistant Editor, 2016 - 2018

## Memberships / Tasks in Scientific Organizations

Onkoloji ve İmmünoterapi Derneği, Chairman, 2021 - Continues, Turkey

ESMO, Principal Member, 2004 - Continues

ASCO, Principal Member, 2003 - Continues

Türk Tıbbi Onkoloji Derneği, Principal Member, 2001 - Continues

Onkoloji ve İmmünoterapi derneği, Vice President, 2018 - 2021, Turkey

Türk Tıbbi Onkoloji Derneği (TTOD), Secretary General, 2014 - 2016

## Scientific Refereeing

European Journal Of Breast Health, Other Indexed Journal, December 2020  
Project Supported by Higher Education Institutions, BAP Research Project, Istanbul University, Turkey, December 2020  
European Journal of Breast Health, Other Indexed Journal, October 2020  
European Journal Of Breast Health, Other Indexed Journal, June 2020  
European Journal of Breast Health, Other Indexed Journal, April 2020  
European Journal of Breast Health, Other Indexed Journal, December 2019  
European Journal of Breast Health, Other Indexed Journal, October 2019  
European Journal Of Breast Health, Other Indexed Journal, September 2019  
European Journal Of Breast Health, Other Indexed Journal, May 2019  
European Journal Of Breast Health, Other Indexed Journal, June 2017

## Tasks In Event Organizations

Oyan Uluç B., Marmara Onkoloji Derneği 2021/12-13 Haziran Akciğer Sempozyumu, Scientific Congress, İstanbul, Turkey, Haziran 2021  
Molinas Mandel N., Oyan Uluç B., Arıbal M. E. , Çelik L., Esen İçten G., Beşe N., Uras C., Çelet Özden B., Yücel A., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, Ocak 2021  
Uras C., Güllüoğlu M. B. , Bese F. N. , İcten S. G. , Çelik L., Arıbal M. E. , Taşkın F., Başaran G., Oyan Uluç B., Sönmez Ö., et al., 4. International breast cancer conference (Breastanbul 2020), Scientific Congress, İstanbul, Turkey, Ekim 2020  
Oyan Uluç B., AACR'dan ASCO'ya Onkoloji pratiğimize yansiyacaklar kongresi (e-kongre), 13-14 Haziran 2020., Scientific Congress, İstanbul, Turkey, Haziran 2020  
Oyan Uluç B., SÖNMEZ Ö., Türk Tıbbi Onkoloji Deneği Meme Tümörleri Kursu, Scientific Congress, İstanbul, Turkey, Şubat 2020  
Oyan Uluç B., Meme kanserinde 2020 Güncel Tedavi Yaklaşımları Sempozyumu, Scientific Congress, Ankara, Turkey, Şubat 2020  
Arıbal M. E. , OYAN ULUÇ B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, Ocak 2020  
Oyan Uluç B., 6th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, Antalya, Turkey, Aralık 2019  
Oyan Uluç B., European Hematology Oncology Conference 2019, Scientific Congress, İstanbul, Turkey, Ekim 2019  
Oyan Uluç B., 1. İmmüno-Onkoloji okulu, Scientific Congress, İstanbul, Turkey, Nisan 2019  
Arıbal M. E. , Oyan Uluç B., Meme Kanserinde Yeni Yaklaşımlar Eğitim Toplantısı, Scientific Congress, İstanbul, Turkey, Ocak 2019  
Oyan Uluç B., BREASTANBUL 3rd Breast Cancer Conference, Scientific Congress, İstanbul, Turkey, Ekim 2018  
Oyan Uluç B., 5th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, Scientific Congress, İstanbul, Turkey, Kasım 2017

## Edit Congress and Symposium Activities

Kanserde İmmüno-Onkolojik ve Moleküler Onkolojik Tedaviler Kursu, Invited Speaker, İstanbul, Turkey, 2021  
Marmara Onkoloji Derneği Akciğer Kanseri sempozyumu, Invited Speaker, İstanbul, Turkey, 2021  
Immunotherapy and unknowns in metastatic lung cancer (WEBTARGED), Invited Speaker, İstanbul, Turkey, 2021  
6th International Senatürk May Day, Invited Speaker, İstanbul, Turkey, 2021  
Hedef Kanser 2021 Online Kongre, Moderator, İzmir, Turkey, 2021  
Onkoloji ve İmmünoterapi Derneği akşam toplantısı, Moderator, İstanbul, Turkey, 2021  
İnteraktif Onkoloji kursları-III, Moderator, İstanbul, Turkey, 2021  
Türk Cerrahi Derneği-SENATÜRK Senoloji Akademisi, Meme Cerrahisi Temel Uzmanlık Eğitimi Programı (Çevrim-içi sürekli eğitim), Invited Speaker, İstanbul, Turkey, 2021  
TTOD-Hasta Dernekleri IO eğitimi İmmünoterapi toplantısı, Invited Speaker, İstanbul, Turkey, 2021

Türk Tıbbi Onkoloji Derneği (TTOD) webinar, Invited Speaker, İstanbul, Turkey, 2021  
VII. Nadir Tümörler Sempozyumu, IZOG 2021, Invited Speaker, İzmir, Turkey, 2021  
Meme Kanseri 2021 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, Ankara, Turkey, 2021  
8th Lung Cancer Network Virtual Symposium, Invited Speaker, İstanbul, Turkey, 2021  
4. Gençlerle Onkolojiye Bakış Kongresi, Moderator, İzmir, Turkey, 2021  
Marmara Onkoloji Derneği Meme Sempozyumu, Session Moderator, İstanbul, Turkey, 2021  
Meme Kanseri Yeni Yaklaşımlar internet üzerinden eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2021  
TTOD Mentörlerle buluşma toplantıları, Invited Speaker, İstanbul, Turkey, 2021  
6. Onkolojide Güncel Gelişmeler Sempozyumu, Invited Speaker, İstanbul, Turkey, 2021  
İnteraktif Onkoloji kursları-II, Invited Speaker, İstanbul, Turkey, 2020  
MAYMET ve Anadolu Sağlık Merkezi (ASM) Ortak Toplantısı: Meme kanseri için bütüncü multidisipliner iş birliği, Panelists, İstanbul, Turkey, 2020  
10th International Gastrointestinal Cancers Virtual Conference (IGICC), Session Moderator, İstanbul, Turkey, 2020  
Türk Tıbbi Onkoloji Derneği Sanal Kongresi, Panelists, İstanbul, Turkey, 2020  
IMAG 34. Olgu toplantısı, Panelists, İstanbul, Turkey, 2020  
4th International Istanbul Breast Cancer Virtual Conference , Panelists, İstanbul, Turkey, 2020  
4th International Istanbul Breast Cancer Virtual Conference (BREASTANBUL), Session Moderator, İstanbul, Turkey, 2020  
Istanbul Reconstructive Breast Cancer Surgery (IREBS) virtual workshop 2020, Panelists, İstanbul, Turkey, 2020  
Istanbul Reconstructive Breast Cancer Surgery (IREBS) virtual workshop 2020, Panelists, İstanbul, Turkey, 2020  
ESMO Highlights , Invited Speaker, İstanbul, Turkey, 2020  
PRIMO 2020 Turkey” (Practical Recommendations in Immuno &Molecular Oncology), Invited Speaker, İstanbul, Turkey, 2020  
COVID-19 Döneminde HR+ Metastatik Meme Kanseri Tedavisinde Güncellemeler, TTOD webinarı, , Invited Speaker, İstanbul, Turkey, 2020  
Onkolojiokulum.net, Invited Speaker, İstanbul, Turkey, 2020  
AACR'dan ASCO'ya Onkoloji pratiğimize yansiyacaklar kongresi, Session Moderator, İstanbul, Turkey, 2020  
WebTARGED: İmmünoterapi ve Covid-19, Invited Speaker, İstanbul, Turkey, 2020  
Onkoloji Okulum-Covid Platformu, Invited Speaker, İstanbul, Turkey, 2020  
Onkoloji Okulum-Covid Platformu, Panelists, İstanbul, Turkey, 2020  
Management of Cancer patients in the era of Covid-19 pandemic webinar , Invited Speaker, İstanbul, Turkey, 2020  
ONCOvid-19, Invited Speaker, İstanbul, Turkey, 2020  
Anaplastik Lenfoma Kinaz pozitif küçük hücreli dışı akciğer kanseri tedavisinde kilit konulara çok yönlü yaklaşım, Invited Speaker, İstanbul, Turkey, 2020  
VII. Nadir Tümörler Sempozyumu, Invited Speaker, İzmir, Turkey, 2020  
Türk Tıbbi Onkoloji Derneği (TTOD)-Meme Tümörleri kursu, Invited Speaker, İstanbul, Turkey, 2020  
TTOD-Meme Tümörleri kursu, Moderator, İstanbul, Turkey, 2020  
AKAD 2020: Ulusal Akciğer kanserleri Kongresi, Invited Speaker, Antalya, Turkey, 2020  
3. Gençlerle Onkolojiye Bakış Kongresi, Invited Speaker, Antalya, Turkey, 2020  
Meme kanserinde 2020 Güncel Tedavi Yaklaşımları Sempozyumu, Session Moderator, Ankara, Turkey, 2020  
7th Lung Cancer Network «From the Bench to Bedside, Invited Speaker, Athens, Greece, 2020  
Meme kanserinde yeni yaklaşımlar eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2020  
Rektum kanseri tedavisinde konsensus toplantısı: İstanbul deklarasyonu, Invited Speaker, İstanbul, Turkey, 2020  
Marmara Anadolu Yakası Meme Hastalıkları Mezuniyet Sonrası Eğitim Toplantıları (MAYMET)- Meme kanserinde biyolojik tedavilerin gelişen yüzü: Hedefler ve araçlar, Invited Speaker, İstanbul, Turkey, 2020  
9th International Gastrointestinal Cancer Conference, Session Moderator, İstanbul, Turkey, 2019  
6th Congress of Mediterranean Multidisciplinary Oncology Forum (MMOF)/3rd International Congress on Oncological Sciences (ICON), Panelists, Antalya, Turkey, 2019  
6th Congress of Mediterranean Multidisciplinary Oncology Forum (MMOF)/3rd International Congress on Oncological Sciences (ICON), Invited Speaker, Antalya, Turkey, 2019  
Antalya Onkolojide iz bırakanlar zirvesi, Invited Speaker, Antalya, Turkey, 2019

Meme kanseri: Çalışmalar ışığında deneyim paylaşımı, Session Moderator, İstanbul, Turkey, 2019  
Comprehensive Genomic Profiling Istanbul Preceptorship, Invited Speaker, İstanbul, Turkey, 2019  
15. Ulusal Meme Hastalıkları Kongresi, Invited Speaker, Antalya, Turkey, 2019  
CRO ve sektör temsilcileri için İmmuno-onkoloji Okulu, Invited Speaker, İstanbul, Turkey, 2019  
Xth Euroasian Hematology Oncology Congress (EHOc 2019), Invited Speaker, İstanbul, Turkey, 2019  
Xth Euroasian Hematology Oncology Congress (EHOc 2019), Invited Speaker, İstanbul, Turkey, 2019  
Kişiselleştirilmiş Tedavi Çağında Göğüs Cerrahları için Onkoloji: TAKD ve TGCD /akciğer Kanseri Çalışma Grubu) Ortak Toplantısı, Invited Speaker, İstanbul, Turkey, 2019  
Istanbul Reconstructive Breast Cancer Surgery (IREBS) Workshop 2019: Level III reconstructive Breast Cancer Surgery Workshop, Panelists, İstanbul, Turkey, 2019  
Istanbul Reconstructive Breast Cancer Surgery (IREBS) Workshop 2019: Level III reconstructive Breast Cancer Surgery Workshop, Panelists, İstanbul, Turkey, 2019  
6. Karadeniz Onkoloji Günleri, Invited Speaker, Trabzon, Turkey, 2019  
2. İmmuno-Onkoloji okulu, Invited Speaker, Ankara, Turkey, 2019  
Best of ASCO İstanbul 2019, Invited Speaker, İstanbul, Turkey, 2019  
Practical Recommendations in Immuno & Molecular Oncology (PRIMO) 2019, Invited Speaker, İstanbul, Turkey, 2019  
Practical Recommendations in Immuno & Molecular Oncology (PRIMO) 2019, Session Moderator, İstanbul, Turkey, 2019  
Tanıdan Tedaviye Akciğer Kanseri Sempozyumu, Session Moderator, Muğla, Turkey, 2019  
1. İmmuno-Onkoloji okulu, Invited Speaker, İstanbul, Turkey, 2019  
Innovative Treatments in Lung Cancer: Scientific-practical conference, Invited Speaker, Kyyiv, Ukraine, 2019  
23. Ulusal Kanser Kongresi (UKK), Invited Speaker, Antalya, Turkey, 2019  
2. Eskişehir Onkoloji Günleri, Panelists, Eskişehir, Turkey, 2019  
Acıbadem Altunizade Hastanesi Kolon Kanseri Farkındalık Söyleşisi, Panelists, İstanbul, Turkey, 2019  
Meme kanserinde yeni yaklaşımlar eğitim toplantısı, Invited Speaker, İstanbul, Turkey, 2019

## Citations

Total Citations (WOS):310

h-index (WOS):10